NPS Pharma Secures $9.75M in Series A Funding, Paving the Way for Shire Acquisition

NPS Pharma is proud to announce a successful funding milestone, having raised $9,750,000 to accelerate its pursuit of innovative pharmaceutical solutions. This significant capital injection is set to enhance our research and development efforts, enabling the expansion of our pipeline with advanced therapies designed to address critical unmet medical needs. The funds will be strategically invested in cutting-edge technology and infrastructure improvements, empowering our teams to conduct more robust clinical trials, streamline manufacturing processes, and expedite the translation of novel compounds from the lab to the market. By bolstering our R&D initiatives, we aim to not only drive breakthrough innovations but also to reinforce our commitment to improving patient outcomes on a global scale. It is important to note that following the acquisition of NPS Pharma by Shire on February 21, 2015, our communications have transitioned, and this page will no longer be actively monitored. For stakeholders and interested parties seeking further updates or additional insights into our ongoing projects, we invite you to visit Shire’s LinkedIn page or their official website at www.shire.com. This funding round underscores the confidence investors have in our vision and capabilities, marking a pivotal step forward in strengthening our market position and accelerating growth. With these newly secured resources, we are even more determined to push the boundaries of pharmaceutical innovation and deliver life-changing solutions that make a lasting impact on the healthcare community worldwide.